
Allena Pharmaceuticals ALNA
Quartalsbericht 2022-Q2
hinzugefügt 15.08.2022
Allena Pharmaceuticals Betriebsaufwand 2011-2026 | ALNA
Betriebsaufwand Jährlich Allena Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 47.6 M | 32 M | 46.9 M | 35.6 M | 21 M | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 47.6 M | 21 M | 36.6 M |
Betriebsaufwand Vierteljährlich Allena Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 6.92 M | 11.6 M | 10.1 M | 12.4 M | 13.7 M | 11.4 M | 9.98 M | 7.92 M | 6.56 M | 7.52 M | 11.3 M | 13.3 M | 11.3 M | 11.6 M | 9.78 M | 9.7 M | 8.14 M | 7.97 M | 6.57 M | 4.36 M | 4.48 M | 5.54 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 13.7 M | 4.36 M | 9.19 M |
Betriebsaufwand anderer Aktien in der Pharmaeinzelhändler
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
FSD Pharma
HUGE
|
15.3 M | - | 5743.5 % | $ 69.7 M | ||
|
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M | ||
|
Happiness Biotech Group Limited
HAPP
|
6.79 M | - | 1.35 % | $ 17.8 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
216 M | $ 16.89 | -2.37 % | $ 789 M | ||
|
AgeX Therapeutics
AGE
|
24.2 M | - | -10.17 % | $ 12.2 K | ||
|
Compugen Ltd.
CGEN
|
40.4 M | $ 2.85 | -5.94 % | $ 266 M | ||
|
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M | ||
|
Coherus BioSciences
CHRS
|
231 M | $ 1.58 | -3.37 % | $ 185 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
78.3 M | - | 2.54 % | $ 160 B | ||
|
AstraZeneca PLC
AZN
|
17.6 B | - | - | $ 96.9 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
158 M | $ 7.46 | -4.73 % | $ 204 M | ||
|
Athira Pharma
ATHA
|
18.7 M | - | - | $ 269 M | ||
|
BiondVax Pharmaceuticals Ltd.
BVXV
|
78.4 M | - | 0.74 % | $ 768 M | ||
|
Galera Therapeutics
GRTX
|
70.6 M | - | -32.59 % | $ 7.61 M | ||
|
Eton Pharmaceuticals
ETON
|
43.6 M | $ 29.73 | -0.77 % | $ 800 M | ||
|
Exelixis
EXEL
|
598 M | $ 50.09 | -1.98 % | $ 13.6 B | ||
|
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M | ||
|
Fortress Biotech
FBIO
|
125 M | $ 2.47 | 7.39 % | $ 68.9 M | ||
|
Forte Biosciences
FBRX
|
70.7 M | $ 22.53 | -5.97 % | $ 292 M | ||
|
Fennec Pharmaceuticals
FENC
|
50.9 M | $ 9.51 | 2.92 % | $ 272 M | ||
|
AbCellera Biologics
ABCL
|
292 M | $ 4.03 | -8.52 % | $ 1.2 B | ||
|
Autolus Therapeutics plc
AUTL
|
145 M | $ 1.57 | -1.26 % | $ 418 M | ||
|
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - | ||
|
BioNTech SE
BNTX
|
512 M | $ 88.94 | -3.32 % | $ 21.5 B | ||
|
Checkmate Pharmaceuticals
CMPI
|
61.5 M | - | - | $ 231 M | ||
|
Galectin Therapeutics
GALT
|
20.1 M | $ 2.22 | -5.74 % | $ 142 M | ||
|
Gilead Sciences
GILD
|
13.5 B | $ 129.56 | -1.9 % | $ 161 B | ||
|
Genmab A/S
GMAB
|
67.9 M | $ 26.79 | -0.41 % | $ 1.73 B | ||
|
Advaxis
ADXS
|
22 M | - | -9.65 % | $ 45.9 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
10.4 M | $ 3.36 | -5.62 % | $ 5.53 M | ||
|
Aeterna Zentaris
AEZS
|
13.3 M | - | 5.93 % | $ 314 M | ||
|
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | ||
|
Grifols, S.A.
GRFS
|
1.64 B | $ 7.67 | -1.6 % | $ 5.21 B | ||
|
AIkido Pharma
AIKI
|
179 M | - | 1.93 % | $ 17.4 M | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
19.3 M | $ 0.72 | -1.76 % | $ 32.9 M | ||
|
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | ||
|
Esperion Therapeutics
ESPR
|
343 M | $ 3.13 | 0.32 % | $ 651 M | ||
|
Aptose Biosciences
APTO
|
24.7 M | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
62.6 M | - | -39.0 % | $ 4.57 M | ||
|
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
163 M | - | -0.23 % | $ 916 M | ||
|
AlloVir
ALVR
|
46.2 M | - | 4.14 % | $ 49.1 M | ||
|
Allakos
ALLK
|
196 M | - | - | $ 28.6 M | ||
|
Arcutis Biotherapeutics
ARQT
|
305 M | $ 21.66 | 0.42 % | $ 2.76 B |